HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: Moderna co-founder Kenneth Chien on the future of mRNA - and Moderna

In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for biotech.

By STAT News · Jun 29, 2026 · via STAT News
STAT+: Moderna co-founder Kenneth Chien on the future of mRNA - and Moderna

Image: STAT News

This is an aggregated industry headline. Read the full story at STAT News

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
As Amgen prepares to defend Tavneos' market approval in the U.S., the company has received a bad omen overseas…
Jun 29, 2026
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
The WeekFierceBiotech ↗
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case f…
Jun 29, 2026
Week’s End: 340B Overhaul Bill and Next FDA Chief in Play
The WeekBriefing
STAT News flagged two developments: a congressional bill to revamp the 340B drug discount program and talk of …
Jun 29, 2026